Linklaters advises Fresenius on the full acquisition of the biopharmaceutical company mAbxience

Linklaters is advising Fresenius on the acquisition of the remaining 45 per cent stake in the leading global biopharmaceutical company mAbxience for a consideration of up to EUR 750 million. Linklaters had previously advised Fresenius in 2022 on the acquisition of a 55 per cent majority stake in mAbxience. With this acquisition, Fresenius is creating a fully integrated biopharma business, which is consolidated within its subsidiary Fresenius Kabi and covers the entire value chain from research to commercialisation. The transaction forms part of the comprehensive #FutureFresenius strategy. 

Linklaters provided Fresenius with comprehensive advice on all legal aspects of the transaction.

The international, cross-practice team at Linklaters was led by Ralph Wollburg (Corporate/M&A) and comprised the partners Arne Kießling (Corporate/M&A), Esteban Arza (Corporate/M&A), Michael Leicht (TMT IP), Jana Hager (Corporate/M&A), Fredrik Löwhagen (Antitrust), Borja Fernandez de Troconiz (Litigation), as well as the managing associates Beatriz Melo (Corporate/M&A), Jose Buigues (Corporate/M&A), Rana Ersoy (Corporate/M&A), and the associates Antonia Mertens (TMT IP), Marc Heusel (TMT IP), Inés Alfaro (Corporate/M&A), Sofia Rubio (Corporate/M&A), Alba Gubia (Antitrust), Maria Angeles Lara (Corporate/M&A) and Teresa Hermosilla (Litigation).

Linklaters provides Fresenius with ongoing advice on all strategic company law matters and complex international transactions.